Previous 10 | Next 10 |
-- Fc-MDNA413 suppresses pro-tumor immune pathways by simultaneously inhibiting IL-4 / IL-13 mediated signaling and proliferation via the Type II IL-4 receptor -- Fc-MDNA413 inhibits in vivo tumor growth alone and in combination with an IL-2 super-agonist in a murine cancer mode...
TORONTO and HOUSTON, March 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and...
TORONTO and HOUSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the publication of two abstracts that have been accepted for el...
Medicenna’s Clinical Advisory Board is comprised of thought leaders in immuno-oncology with experience in clinical development of Proleukin® and next generation IL-2 Dr. Dhingra has a track record of development and approval of cancer therapies and extensive board le...
TORONTO and HOUSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medice...
Medicenna Therapeutics Corp. (MDNA) Q3 2022 Earnings Conference Call February 9, 2022 8:30 a.m. ET Company Participants Fahar Merchant - President & CEO Liz Williams - CFO Martin Bexon - CMO Rosemina Merchant - CDO Dan Ferry - LifeSci Advisors, IR Conference Call Participants Matt Biegler...
Medicenna Therapeutics press release (NASDAQ:MDNA): Q3 GAAP EPS of -$0.09. Medicenna had cash, cash equivalents, and marketable securities of $23.4 million at December 31, 2021. These funds provide the Company with sufficient capital to execute its current planned expenditures through to the ...
-- Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022 -- Preliminary pharmacodynamic data show preferential stimulation of anti-cancer immune cells with MDNA11 treatment in the ABILITY st...
TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 9, 2022 at 8:30 AM E...
TORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the formation of its Scientific Advisory Board (SAB) comprised o...
News, Short Squeeze, Breakout and More Instantly...
Medicenna Therapeutics Corp. Company Name:
MDNA Stock Symbol:
NASDAQ Market:
TORONTO and HOUSTON, Oct. 27, 2023 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ, TSX: MDNA), a clinical-stage immunotherapy company focused on the development of engineered cytokines, announced today that the Company received ...